Stryker (NYSE:SYK) agreed to deal a bone-growth protein to biopharmaceutical firm Mariel Therapeutics, which said it plans to investigate the product as a potential treatment for a variety of conditions.
Financial terms of the deal for Stryker’s bone morphogenetic protein-7 were not disclosed.
Mariel Therapeutics said it plans to research BMP-7’s use as a potential treatment of osteoarthritis, chronic kidney disease and other organ fibrosis conditions, lupus and obesity.
The deal covers the rights to some 450 patents covering the bone-growth protein, plus related clinical and research data and "the associated biologic materials," according to a press release.
BMP-7 has been used in more than 40,000 patients, including in Phase I and Phase II clinical trials involving osteoarthritis patients, according to the release. Mariel said it plans to pursue a Phase IIb/Phase III trial for that condition, as well as Phase I trials for chronic kidney disease and the genetic kidney fibrosis condition known as Alport’s disease.